Eris Lifesciences Limited confirmed receiving penalties from both the BSE and the NSE for non-compliance related to its Board composition requirements. Each exchange imposed a fine of ₹65,000. The company clarified that the violation stemmed from the completion of term for an Independent Director, and they are actively screening candidates to fill the resulting vacancy. Eris emphasized its commitment to regulatory compliance and expects to resolve the issue shortly.
Regulatory Penalty Disclosure
Eris Lifesciences Limited has disclosed that it was penalized by both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for certain regulatory breaches. The penalties were imposed via separate letters dated February 27, 2026.
Details of the Fine
According to the disclosed annexure, each exchange levied a fine of ₹65,000 (Rupees Sixty-Five Thousand only) on the Company. The action taken by the authorities was a fine. The impact on the financial position is quantifiable only to the extent of the total penalty amount, which is ₹1,30,000 across both exchanges.
Nature of the Violation
The contravention committed by the listed entity relates to Non-compliance with the requirements pertaining to the composition of the Board of Directors. Specifically, the issue arose due to the completion of the term of an Independent Director.
Company Response and Remediation
The Company provided clarification stating that it has been actively screening suitable candidates for the subsequent appointment as an Independent Director to fill the anticipated vacancy. Eris Lifesciences Limited affirmed its commitment to ensuring full compliance with all applicable laws and regulatory requirements, expecting to report compliance on this matter soon.
Source: BSE
